证券代码：688114 证券简称：华大智造 公告编号：2023- 033 深圳华大智造科技股份有限公司 关于修订《公司章程》《股东大会议事规则》《董事会议事规 则》及部分治理制度的公告 深圳华大智造科技股份有限公司（以下简称"公司"）于 2023 年 8 月 9 日 召开第一届董事会第十七次会议和第一届监事会第十七次会议，分别审议通过了 《关于修订〈公司章程〉及〈股东大会议事规则〉〈董事会议事规则〉的议案》 《关于修订公司部分治理制度的议案》以及《关于修订〈监事会议事规则〉的议 案》。现将有关情况公告如下： 一、《公司章程》修订情况 为进一步完善公司治理结构，提升公司规范运作水平，根据《中华人民共和 国公司法》《上市公司章程指引（2022 年修订）》《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律、法规及规范性文件的规定，并结合公司实际情况，公司拟对《深圳华大 智造科技股份有限公司章程》（以下简称"《公司章程》"）相关条款进行修订。具 体修订情况如下： | 序号 | 修订前 | 修订后 | | --- | --- | --- | | 1 | 第六 ...

深圳华大智造科技股份有限公司 章程 深圳华大智造科技股份有限公司 章程 第一章 总则 第一条 为维护深圳华大智造科技股份有限公司（以下简称"公司"）、股 东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司章程指引》（以下简称"《章程指引》"）、《上海证券 交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）和其他有关 规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司以发起方式设立，在深圳市市场监督管理局登记并取得营业执照，统一 社会信用代码为 91440300341500994L。 第三条 公司于 2022 年 7 月 26 日经中国证券监督管理委员会（以下简称"中 国证监会"）履行发行注册程序，首次向社会公众发行人民币普通股 41,319,475 股，于 2022 年 9 月 9 日在上海证券交易所（以下简称"上交所"）上市（以下 简称"上市"）。 第四条 公司注册名称：深圳华大智造科技股份有限公司。 英文全称：MGI Tech CO., Ltd ...

证券代码：688114 证券简称：华大智造 公告编号：2023-031 关于部分募投项目由向子公司借款实施变更为 向子公司增资实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增资标的名称：武汉华大智造科技有限公司、青岛华大智造科技有限责 任公司 增资金额：深圳华大智造科技股份有限公司拟对武汉华大智造科技有限 公司（以下简称"武汉智造"）增资 126,437.19 万元；拟对青岛华大智造科技有 限责任公司（以下简称"青岛智造"）增资 19,787.44 万元。本次增资金额全部 计入新增注册资本。本次增资完成后，武汉智造、青岛智造仍为公司全资子公司。 本次增资交易对象为公司合并报表范围内的全资子公司。 本次增资不构成《上市公司重大资产重组管理办法》规定的重大资产重 组。 本次增资的实施不存在重大法律障碍。 深圳华大智造科技股份有限公司（以下简称"公司""本公司"或"华大智 造"）于 2023 年 8 月 9 日召开第一届董事会第十七次会议、第一届监事会第十 七次会议，审议通过了《关于部分募投项目由向子公 ...

深圳华大智造科技股份有限公司 董事会秘书工作细则 深圳华大智造科技股份有限公司 董事会秘书工作细则 （三）曾被证券交易所公开认定为不适合担任上市公司董事会秘书; 第一章 总则 第一条 为明确深圳华大智造科技股份有限公司（以下简称"公司"或"本 公司"）董事会秘书的职责权限，规范董事会秘书的行为，根据《中华人民共和 国公司法》（以下简称《公司法》）《深圳华大智造科技股份有限公司章程》（以下 简称《公司章程》）及其他有关规定，制定本工作细则。 第二条 董事会秘书为公司的高级管理人员，对公司和董事会负责。法律、 行政法规、部门规章及《公司章程》等对公司高级管理人员的有关规定，适用于 董事会秘书。 董事会秘书是公司与上海证券交易所（以下简称"交易所"）之间的指定联 络人。 第三条 公司设立证券事务部作为董事会秘书履行职责的日常工作机构，由 董事会秘书负责管理。 第二章 任职资格 第四条 董事会秘书应当具备履行职责所必需的财务、管理、法律专业知识, 具有良好的职业道德和个人品德，具备履行职责所必须的工作经验，并取得交易 所颁发的董事会秘书资格证书。 第五条 有下列情形之一的人士不得担任公司董事会秘书： （一）有《公司法 ...

深圳华大智造科技股份有限公司 总经理工作细则 第二条 公司设置总经理一名，其他高级管理人员是指《公司章程》规定的 相关人员。 第三条 总经理由董事会聘任或解聘，对董事会负责。 第四条 总经理主持公司日常生产经营和管理工作，组织实施董事会决议。 第二章 总经理的任职资格 第五条 总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营 管理能力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统 揽全局的能力； 深圳华大智造科技股份有限公司 总经理工作细则 第一章 总则 第一条 为明确深圳华大智造科技股份有限公司（以下简称"公司"或"本 公司"）总经理职责权限，规范总经理的组织和行为，提高决策效率，根据《中 华人民共和国公司法》（以下简称《公司法》）和《深圳华大智造科技股份有限公 司章程》（以下简称《公司章程》）的规定，制定本细则。 （三）具有一定年限的企业管理或经济工作经历，精通本行业的生产经营业 务，掌握国家政策、法律、法规； （四）诚信勤勉、廉洁奉公、民主公道； （五）有较强的使命感和积极开拓的进取精神。 第六条 有下列情形之一的，不得担任本公司总 ...

第一章 总则 第一条 为规范深圳华大智造科技股份有限公司（以下简称"公司"）募集 资金的存储、使用与管理，提高募集资金的使用效率和效益，保障募集资金的安 全，维护投资者的合法权益，根据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等有关法律、法规、规章、规范性文件以及《深 圳华大智造科技股份有限公司章程》（以下简称《公司章程》）的规定，结合公司 的实际情况，制定本制度。 深圳华大智造科技股份有限公司 募集资金管理制度 深圳华大智造科技股份有限公司 募集资金管理制度 第二条 本制度所称募集资金，是指公司通过向不特定对象发行证券（包括 首次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换 公司债券等）以及向特定对象发行证券募集的资金，但不包括公司实施股权激励 计划募集的资金。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《中华人民共 和国证券法》要求的会计师事务所出具验资报告。公司按照招股说明书、募集说 明书 ...

深圳华大智造科技股份有限公司 董事会提名委员会工作细则 深圳华大智造科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第一条 为规范深圳华大智造科技股份有限公司（以下简称"公司"）领导人 员的产生，优化董事会和高级管理层的组成，完善公司治理结构，根据《中华人 民共和国公司法》、《中华人民共和国证券法》、《深圳华大智造科技股份有限公司 章程》（以下简称《公司章程》）及其他有关规定，公司特设立董事会提名委员会， 并制定本细则。 第二条 提名委员会是董事会设立的专门工作机构。主要负责对公司董事和 高级管理人员的人选、选择标准和程序进行审查、研究，并提出建议。 第二章 人员组成 第三条 提名委员会成员由三名或以上董事组成，其中独立董事占多数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一以上提名，并由董事会全体董事的过半数通过产生。 第五条 提名委员会设主任委员（召集人）一名，由独立董事委员担任，负 责主持委员会工作；主任委员（召集人）在委员内选举，并报请董事会批准产生。 第六条 提名委员会任期与董事会任期一致，委员任期届满，可连选连任。 期间如有委员不再担任董事职务，即自动失 ...

提名人深圳华大智造科技股份有限公司董事会，现提名孙健先生为深圳华大 智造科技股份有限公司第二届董事会独立董事候选人，并已充分了解被提名人职 业专长、教育背景、工作经历、兼任职务等情况。被提名人已书面同意出任深圳 华大智造科技股份有限公司第二届董事会独立董事候选人（参见该独立董事候选 人声明）。提名人认为，被提名人具备独立董事任职资格，与深圳华大智造科技 股份有限公司之间不存在任何影响其独立性的关系，具体声明如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部 门规章及其他规范性文件，具有五年以上法律、经济、财务、管理或者其他履行 独立董事职责所必需的工作经验，并已根据《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》及相关规定取得独立董事资格证书。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《公司法》关于董事任职资格的规定； 独立董事提名人声明 （二）《公务员法》关于公务员兼任职务的规定； （三）中央纪委、中央组织部《关于规范中管干部辞去公职或者退（离）休 后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定； （四）中央纪委、教育部、 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 342 million in 2022, reflecting a growth of 15% year-over-year[11]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year growth of 15%[16]. - The company's operating revenue for 2022 was CNY 4,230,800,610, representing a year-on-year increase of 7.69%[22]. - The total profit reached 2,531.39 million RMB, showing a significant increase of 324.70% compared to the previous year[44]. - The net profit attributable to shareholders for 2022 reached CNY 2,026,449,580, a significant increase of 319.04% compared to the previous year, primarily due to a settlement with Illumina resulting in a net compensation of USD 325 million[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.43% to CNY 264,109,949.78, influenced by changes in market demand and an increase in R&D expenses[25]. - The company achieved a main business revenue of CNY 4,206.88 million, an increase of 7.96% year-on-year, while the main business cost rose by 50.19% to CNY 1,952.75 million[158]. - The gross profit margin for the specialized equipment manufacturing industry decreased by 13.05 percentage points to 53.58%[158]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 3.60 per 10 shares, totaling RMB 149,160,502.80, which represents 7.36% of the net profit attributable to shareholders for 2022[4]. - As of December 31, 2022, the total share capital of the company was 414,334,730 shares[4]. Research and Development - Investment in R&D is set to increase by 15% in 2023, emphasizing innovation and the development of cutting-edge technologies[12]. - The company reported a total R&D investment of approximately ¥814.37 million, representing a 33.88% increase compared to the previous year, and accounting for 19.25% of total revenue[122]. - The number of R&D personnel increased by 42.25% to 1,010, with R&D staff now comprising 36.01% of the total workforce[121]. - The R&D expenditure as a percentage of operating revenue was 19.25%, an increase of 3.77 percentage points compared to the previous year[24]. Market Expansion and Strategy - The company provided a positive outlook for 2023, projecting a revenue growth of 20% driven by new product launches and market expansion initiatives[12]. - The company is planning to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[12]. - Strategic acquisitions are on the agenda, with plans to acquire two smaller biotech firms to bolster R&D capabilities and product offerings[12]. - The company is focusing on increasing its international sales, with a goal of achieving 40% of total revenue from overseas markets by 2025[12]. - The company has established five new subsidiaries in key global markets, including the USA and Brazil, and opened five customer experience centers to enhance local business development and support[36]. Operational Efficiency - The company aims to enhance its operational efficiency, targeting a reduction in costs by 10% through process optimization and technology integration[12]. - Future guidance indicates an expected EBITDA margin improvement to 25% by the end of 2023, up from 20% in 2022[12]. Governance and Compliance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[6]. - The governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring effective and stable operations[200]. - The company has established various governance rules and management systems to ensure compliance with laws and regulations, providing a framework for standardized corporate governance[200]. Risks and Challenges - The company has detailed various operational risks in the report, which can be found in the "Management Discussion and Analysis" section[3]. - The company faces risks related to product upgrades and technological updates, which could impact future performance if not managed effectively[133]. - The company is subject to various intellectual property litigation risks across 20 countries, which may impact its business operations and market expansion[135]. - The company is facing risks related to the loss of core technical talent and potential leakage of core technologies due to intensified competition in the industry[134]. Product Development and Innovation - New product development includes the introduction of the stLFR technology, which is expected to enhance genomic analysis capabilities and attract new customers[12]. - The company launched the DNBSEQ-T20×2 ultra-high-throughput sequencer, capable of reducing the cost of whole genome sequencing to below $100[33]. - The company has commercialized 12 types of sequencing proteins, delivering over 660 liters, and is set to begin production of 19 types of dNTP products at its Wuhan base in 2023[39]. - The company has developed a full range of gene sequencers, including small desktop sequencers and large-scale sequencers, to meet diverse user needs in various application scenarios[127]. Customer and Supplier Relationships - The company’s top five customers contributed CNY 1,354.50 million in sales, accounting for 32.02% of total annual sales, with related party sales making up 18.33%[166]. - The top five suppliers accounted for 33.16% of total procurement, with the largest supplier contributing 507,471,841.37 RMB, or 15.93% of total procurement[169]. - The company did not rely heavily on a single supplier or customer, as indicated by the absence of significant dependency on the top five suppliers and customers[168][169]. International Operations - The company has expanded its global business network, employing over 2,800 people and establishing 21 overseas subsidiaries across various countries[46]. - The company aims to enhance its global market presence by establishing training, logistics, and R&D centers across four major regions: China, Asia-Pacific, Europe, and the Americas[191]. Financial Management - The company plans to mitigate foreign exchange risks by utilizing forward foreign exchange contracts and adjusting currency holdings based on funding needs[146]. - The company’s cash flow from operating activities increased by 32.43% to CNY 1,421,245,347.84, driven by the compensation received from Illumina[156].

Financial Performance - The company reported a total revenue of $1.8 billion for the fiscal year 2022, representing a 15% increase year-over-year [13]. - The company's operating revenue for 2022 was CNY 4,230,800,610, representing a year-on-year increase of 7.69% [24]. - The total profit reached 2,531.39 million yuan, reflecting a significant year-on-year growth of 324.70% [65]. - The net profit attributable to shareholders increased by 319.04% to CNY 2,026,449,580, primarily due to a settlement with Illumina resulting in a net compensation of USD 325 million [27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.43% to CNY 264,109,949, influenced by changes in product sales structure and increased R&D expenses [27]. - The net cash flow from operating activities rose by 32.43% to CNY 1,421,245,347, also benefiting from the Illumina settlement [27]. - Basic earnings per share grew by 304.62% to CNY 5.26, reflecting the significant increase in net profit [26]. - Diluted earnings per share also rose by 304.65% to CNY 5.22, consistent with the net profit growth [26]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 3.60 per 10 shares, totaling RMB 149,160,502.80, which represents 7.36% of the net profit attributable to shareholders for 2022 [5]. - The total share capital as of December 31, 2022, is 414,334,730 shares [5]. Research and Development - Investment in R&D increased by 30%, focusing on new technologies and product development [14]. - The R&D expenditure as a percentage of operating revenue increased to 19.25%, up from 15.48% in the previous year [26]. - In 2022, the company invested CNY 814.37 million in R&D, a year-on-year increase of 33.88%, accounting for 19.25% of total revenue [42]. - The company applied for 369 new patents and obtained 123 patents, including 85 invention patents, enhancing its core technology capabilities [42]. - The company has developed core technologies in various fields, including high-precision temperature control and automated sample processing, all sourced from independent research and development [153]. Market Expansion and Strategy - The company expects revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion [14]. - The company plans to expand its market presence in Asia, targeting a 15% market share by 2025 [14]. - The company is focusing on expanding its market presence in Europe and the Americas with tailored product versions [12]. - The company has established a global business network, with access to major markets across six continents and R&D centers in the USA and Latvia, enhancing its international presence [178]. Product Development and Innovation - The company launched a new product line that is expected to contribute $200 million in revenue in the first year [14]. - The company launched multiple new product series, including the E, G, and T series in gene sequencing instruments, and various automation devices in laboratory automation [40]. - The company has developed high-throughput single-cell sequencing kits, achieving a cell capture rate of 50%-70% [14]. - The company introduced the DNBSEQ-G99 product, a small to medium throughput instrument, which can complete PE150 sequencing in 12 hours, suitable for small sample applications [145]. - The company launched the HotMPS high-throughput sequencing kit in several European countries, compatible with DNBSEQ-T7 and DNBSEQ-G400 series, featuring new sequencing substrates and enzymes [79]. Operational Risks and Governance - The company has detailed various operational risks in the report, which can be found in the section on risk factors [4]. - The company has not disclosed any special arrangements for corporate governance [7]. - The company has no non-operating fund occupation by controlling shareholders or related parties [7]. - There are no violations of decision-making procedures regarding external guarantees [7]. Market Conditions and Competition - The company operates in a highly competitive gene sequencing market, with Illumina and Thermo Fisher holding over 90% market share, posing significant competition risks [186]. - The company is at risk of fluctuating gross margins due to varying prices and profit margins across its diverse product matrix [193]. - The company acknowledges the potential negative impacts of international trade tensions on its overseas business operations, which could affect sales and growth [200]. Employee and Talent Management - The company employs over 2,800 staff globally, with 1,010 in R&D, representing 36.01% of the workforce, emphasizing its focus on talent acquisition [63]. - The R&D team consists of 1,010 personnel, accounting for approximately 36.01% of total employees, with over 50% holding master's degrees or higher, driving continuous innovation in gene sequencing and laboratory automation [180]. - The company has established a comprehensive training system to enhance employee skills and core competitiveness [64]. Settlements and Legal Matters - The company reached a settlement with Illumina, resulting in a net compensation of $325 million, allowing it to officially enter the U.S. market for sequencing products [50]. - The company is subject to potential impacts from ongoing intellectual property litigation in multiple countries, which could affect its market expansion [184]. Quality Management and Certifications - The company has established a comprehensive quality management system, obtaining 33 global certifications, including 8 international standards and 4 drug regulatory approvals [54]. - The company achieved a cumulative total of 213 medical device registrations and certifications, including 24 domestic and 189 foreign [155].